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Correction to:  PharmacoEconomics ‑ Open  
https ://doi.org/10.1007/s4166 9‑019‑0124‑5
Multiple errors have been identified in the article including 
in the main findings.
For example, two sentences in the abstract, Results, which 
read:
“Variable costs (HD: US$172, 359.15; PD: US$20, 488.79) 
were found to be the biggest cost drivers for both treatment 
modalities. The annual cost of HD per patient (US$205, 
681.40) was higher than PD (US$25, 282.00 per patient), 
even though the difference was not statistically significant 
(p = 0.175)”.
Should have read:
“Fixed costs were the principal cost driver for HD 
($16,231.45) while variable costs were the principal cost 
driver for PD (US$20,488.79). The annual cost of HD per 
patient (US$31,993.12) was higher than PD (US$25,282.00 
per patient), even though the difference was not statistically 
significant (p = 0.816)”.
Errors were also identified in the following locations:
• Section “3 Results”
• Section “4 Discussion”
• Table 1
• Table 3
• Figure 2
• Table 6
• Section “5 Conclusion”
The article has now been updated to correct the errors.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution-NonCommercial 4.0 International License 
(http://creat iveco mmons .org/licen ses/by-nc/4.0/), which permits any 
noncommercial use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the 
source, provide a link to the Creative Commons license, and indicate 
if changes were made.
The original article can be found online at https ://doi.org/10.1007/
s4166 9-019-0124-5.
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